| Document |
Document Title |
|
WO/2024/012540A1 |
Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, egg secreted proteins, etc. (hereinafter referred to as "Schistosoma eggs and secretions and exc...
|
|
WO/2024/012073A1 |
Provided are an osteosarcoma organoid model and a construction method therefor. The osteosarcoma organoid model at least comprises a biological scaffold, osteosarcoma cells, and exosomes derived from mesenchymal stem cells, wherein the o...
|
|
WO/2024/014643A1 |
The present invention relates to a method for producing immunocytes having improved cytotoxicity. The production method can provide immunocytes having improved cytotoxicity, and the immunocytes can be utilized as various cell therapy pro...
|
|
WO/2024/015608A1 |
The present disclosure relates to a method of determining effectiveness of corneal stromal stem cell therapy through evaluation of stemness markers in the CSSC sample for stem cell stability, determining a ratio of inflammation of the CS...
|
|
WO/2023/230143A9 |
The present disclosure relates generally to methods and systems for the analysis, development, testing, and/or optimization, of culture media and/or culture conditions for extracellular vesicle production; culture media analyzed, develop...
|
|
WO/2024/007129A1 |
The present invention relates to the technical field of biopharmaceuticals, and in particular to a humanized B7H3 antibody or an antigen-binding fragment thereof. According to the present invention, two antibodies, hu9C8 and hu5B6, are d...
|
|
WO/2024/010157A1 |
The present invention relates to a composition containing hair follicle cells isolated from the human scalp. Specifically, the present invention relates to a composition for the treatment or prevention of hair loss, which is designed to ...
|
|
WO/2024/010317A1 |
The present invention relates to the establishment of an immortalized erythroid progenitor cell line and, more specifically, provides an immortalized erythroid progenitor cell line for the production of red blood cells, wherein the proge...
|
|
WO/2024/007850A1 |
An anti-influenza B virus antibody, and a reagent and a kit for detecting influenza B virus, relating to the technical field of antibodies. The anti-influenza B virus antibody comprises a heavy chain complementarity-determining region an...
|
|
WO/2024/010020A1 |
The present invention addresses the problem of providing: a matured cultured cell sheet which is constructed from cardiac myocytes without using a specific medical agent; and a method for producing the same. The present invention also ad...
|
|
WO/2024/009226A1 |
The present disclosure relates to improved cellular intermediates and potency assays for obtaining the same. Such intermediates and assays may be suitable for use in providing cellular compositions for treating various inflammatory disor...
|
|
WO/2024/008139A1 |
Disclosed are an optimized amplification and at-scale production method for regulatory T cells. The method comprises the following steps: preparing a resuspension comprising umbilical cord blood regulatory T cells; transferring the resus...
|
|
WO/2024/010085A1 |
Provided is a mutant OCT3/4 protein that is capable of inducing reprogramming of somatic cells at higher efficiency than an OCT3/4 protein composed of a natural amino acid sequence. Also provided is a method for efficiently producing iPS...
|
|
WO/2024/009946A1 |
The present invention addresses the problem of providing a method for testing the effectiveness of a PARP inhibitor against ovarian cancer. Said problem is solved by a method for testing the effectiveness of a PARP inhibitor against ovar...
|
|
WO/2024/010763A1 |
Platelets are similar in density to PBMC and thus are contaminants of PBMC isolated by Ficoll density gradient centrifugation the established procedure for preparing PBMC. Platelets are very sticky and often interfere with experiments re...
|
|
WO/2024/008274A1 |
The invention relates to methods for modifying T regulatory cells by introducing RNApolynucleotides thereto by electroporation, and further pertains to the modified Treg cells and their compositions and uses.
|
|
WO/2024/010955A1 |
Provided are methods of manufacturing cells. The methods comprise expanding cells in the presence of inosine, and harvesting the cells after expansion. In certain embodiments, the cells are genetically modified. For example, the cells ma...
|
|
WO/2024/010727A2 |
The present disclosure relates to cell growth supplements using dairy-based materials for cell culture and other applications. Some embodiments are directed to sequentially culturing cells in a culture medium comprising factors to increa...
|
|
WO/2024/009246A1 |
The present application relates to a culture medium for the culture of intestinal organoids characterized in that it comprises neuregulin 1 (NRG1) and all-trans retinoic acid (atRA). It also relates to a method using this medium to cultu...
|
|
WO/2024/010074A1 |
The present invention provides a protein having an amino acid sequence of SEQ ID NO: 2 and a mutant thereof, a polynucleotide encoding the protein, a transformant including the polynucleotide, and a steviol glycoside using the protein an...
|
|
WO/2024/010933A1 |
Compositions and methods are provided that relate to the cryopreservation of human Treg cells. The Treg cells can be provided for therapeutic use, e.g. administration to a patient in need thereof. The cryopreservation methods disclosed h...
|
|
WO/2024/010064A1 |
This cell culture apparatus is equipped with a hydrogel chamber, a culture vessel and a pneumatic device. The hydrogel chamber holds a hydrogel for culturing a cell. The culture vessel is equipped with a first culture solution storage un...
|
|
WO/2024/007351A1 |
Provided are a feeding cell expressing a recombinant antigen protein, a method for preparing same, and use thereof. The feeding cell expresses the recombinant antigen protein that can be recognized by effector cells on the surface, there...
|
|
WO/2024/010118A1 |
A novel antibody, which specifically binds to BDCA-2, according to the present invention recognizes BDCA-2 at a similar level to known antibodies, and mediates the internalization of BDCA-2 from the surface of plasmacytoid dendritic cell...
|
|
WO/2024/010278A1 |
The present invention pertains to artificial skin using fibroblasts and keratinocytes, and more specifically to a method for manufacturing artificial skin using cells differentiated from induced pluripotent stem cells. To this end, a met...
|
|
WO/2024/009636A1 |
Provided are a well plate that exhibits exceptional cell adhesion properties and low drug sorption properties, and a culture method.　Specifically provided is a well plate having a bottom surface member and a well side wall member, wher...
|
|
WO/2024/007984A1 |
Disclosed are a microfluidic 3D printing technology-based cultured meat production device and a use thereof. The device comprises a printing nozzle, a printing moving system, a loading platform, a sample injection system and a base. The ...
|
|
WO/2024/007982A1 |
Provided are a microfluidic biomimetic fiber for producing cell cultured meat, a preparation method therefor and the use thereof. The microfluidic biomimetic fiber has a shell-core structure, wherein the shell is formed by means of cross...
|
|
WO/2024/008874A1 |
The present invention relates to a method of isolating a stem cell line derived from a tissue from a primary meristem in a leaf of a plant, comprising the steps of (a) sterilizing at least a part of the leaf containing the central or oth...
|
|
WO/2024/010872A1 |
A method of growing isolated mitochondria includes selecting a source of mitochondria and stem cells, extracting the stem cells and the mitochondria from the source and segregating the stem cells and the mitochondria into first and secon...
|
|
WO/2024/008116A1 |
Provided is a robust nasal organoid culture system and fully characterized 2D and 3D in-vitro generated organoids, and methods of using the organoids. The nasal organoids contain a population of differentiated nasal epithelial cells havi...
|
|
WO/2024/008776A1 |
The present invention concerns a human T cell or NK cell comprising a nucleic acid construct which comprises a transgene which is placed under the control of a regulatory polynucleotide inducible by a deficiency in at least one essential...
|
|
WO/2024/010053A1 |
The purpose of the present invention is to provide: an embryoid body cell composition which exhibits high proliferation capability and/or differentiation potency during the differentiation step for differentiating into the subsequent tar...
|
|
WO/2024/010119A1 |
The present invention relates to CAR-T cells that secrete EphA2 T cell engager and target EGFRvIII, which is a mutant EGFR, and according to the present invention, EGFRvIII CAR-T cells that secrete the EphA2 T cell engager exhibit specif...
|
|
WO/2024/011248A1 |
Compositions and articles comprising scleroglucan that can be used for culturing and enumerating microorganisms even after exposure to sterilizing doses of radiation. The compositions also include one or more water swellable polymers oth...
|
|
WO/2024/008140A1 |
A high recovery rate in-vitro amplification method for cryo-preserved umbilical cord blood regulatory T cells, which comprises the following steps: performing recovery on cryo-preserved umbilical cord blood regulatory T cells after prima...
|
|
WO/2024/010921A1 |
A method of making a tissue reference control block is disclosed wherein cancer cells are selected with a known positivity or negativity for a specific marker and cancer cells are grown to a certain phase. The cancer cells are screened f...
|
|
WO/2024/008810A1 |
An in vitro method for producing a population of pancreatic endocrine (PEC) cells comprising the steps of i) differentiating a population of pancreatic endoderm (PE) cells into pancreatic endocrine progenitors, in which the differentiati...
|
|
WO/2024/008773A1 |
The present invention relates to a method of producing a population of differentiated cells from pluripotent stem cells (PSC) in suspension culture in a bioreactor, the method comprising (i) cultivating the PSC under suitable conditions ...
|
|
WO/2024/009093A1 |
The present invention relates to a cell which expresses a tri-specific chimeric antigen receptor (CAR) with multiple antigen specificities. The cell targets multiple antigens characteristic of acute myeloid leukemia (AML), specifically C...
|
|
WO/2024/010730A2 |
Cryopreserved biomaterials are rewarmed with resistive heating methods. The method is scalable to large number of specimens. The cryopreserved biomaterial is in thermal contact with an electrical conductor. The electrical conductor is co...
|
|
WO/2024/010279A1 |
The present invention relates to artificial skin using fibroblasts and keratinocytes, and, more specifically, to a device for producing artificial skin using cells differentiated from induced pluripotent stem cells. In this regard, the d...
|
|
WO/2024/010067A1 |
The purpose of the present invention is to provide a nucleic acid molecule, a vector, recombinant cells, and a drug for treating a central nervous system disease which is likely to migrate into the central nervous system. The nucleic aci...
|
|
WO/2024/006764A1 |
A biotechnological chemically induced dimerization (CID) tool with potential technological and therapeutic applications thereof. These CID systems are used in biological research to control numerous outputs in living organisms, such as i...
|
|
WO/2024/000073A1 |
Disclosed herein are media, kits, and methods for differentiating mammalian progenitor cells to a downstream lineage of cells. Embodiments of disclosed media, methods and kits may be used to differentiate mammalian progenitor cells to te...
|
|
WO/2024/005564A1 |
The present invention relates to a pharmaceutical composition comprising human pluripotent stem cell-derived mesenchymal stem cells as an active ingredient for the prevention and treatment of rotator cuff syndrome or rotator cuff tears. ...
|
|
WO/2024/000223A1 |
Provided are a modified viral envelope protein and the use thereof, and a pseudotype virus-like particle containing the modified viral envelope protein and the use thereof. The modified viral envelope protein can improve the infection ef...
|
|
WO/2024/006926A2 |
The present disclosure provides editable cell lines, including the use of gene editing proteins to produce the cell lines. The editable cell lines are able to express antibody constant regions that can serve as a platform for the antibod...
|
|
WO/2024/001844A1 |
Provided are a new nanobody targeting human HER2/ErbB2 (HER2-Nanobody, HER2-Nb), a method for preparing same, and use thereof. The monoclonal nanobody efficiently and specifically binds to a purified HER2 protein and HER2 on the surface ...
|
|
WO/2023/186113A9 |
Disclosed are an antigen-binding protein targeting PD-L1 and CD40, preparation therefor, and use thereof. The antigen-binding protein targeting PD-L1 and CD40, by means of blocking a PD-1/PD-L1 inhibitory signaling pathway, acting on an ...
|
